Objective: In this study, biodegradable Chitosan Ascorbate Microsphere (CAMs) and mannosylated chitosan ascorbate microsphere (m-CAMs) prepared for targeting towards alveolar macrophages to treatment of pulmonary tuberculosis. Significance: Ascorbic acid is an antioxidant and reported killing effect on mycobacterium by induces fenton reaction. This study enlightens the possible benefits of adding antioxidant properties of ascorbic acid with chitosan microsphere to an anti-tuberculosis regimen and mannosylation of microsphere significantly induce the targetability of antitubercular drug to alveolar macrophages. Methods: CAMs prepared by firstly salification of chitosan by ascorbic acid then ionic gelation with STPP and m-CAMs prepared by incubation method and purified for further studies. The physicochemical, in vitro and in vivo characterizations of both formulations were carried out. Results: The size of microspheres (both CAMs and m-CAMs) were found to be in range of 3.40-4.81µm. Evident changes were observed in crystallinity and structure of both carrier systems and depicted by Fourier transform infrared (FTIR), Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies. In vitro lung deposition study of microspheres showed favourable aerodynamic properties for deep lung delivery (MMAD 2.0-3.8 μm) and, thus, show potential for an application as inhalable tuberculosis therapy. The drug release showed the biphasic pattern of release, i.e., initial burst (30-45% up to 8 h) followed by a slower sustained release pattern (more than 80% up to 72 h) in both simulated lung fluids. Optimized formulations exhibited lower cytotoxicity and bio distribution studies demonstrated the efficiency of m-CAMs for spatial delivery of INH to alveolar tissues. CAMs and m-CAMs evidenced minor cytotoxicity on lung epithelial cells (A549 cell lines). Conclusion: m-CAMs thus has a promising potential to be explore as an effective carrier system for delivery of antitubercular drugs regimen.
INTRODUCTION
Worldwide, Tuberculosis (TB) is one of the top 10 causes of death and the leading cause from a single infectious agent (above HIV/AIDS) 1 . The World Health Organization has set a deadline to end the TB epidemic by 2035, which includes a 90-95% reduction in TB incidence and in the number of TBrelated deaths 2, 3 . The causative agent Mycobacterium tuberculosis (MTB), an intracellular parasitic pathogen resides in alveolar Macrophage (AM) that mainly affects the respiratory tract.
The current treatment regimen for TB consists of administering the drugs via oral or parenteral routes which remain challenging for clinicians because of high systemic delivery of single or multiple drug associated with various problems i.e. patient incompliance, toxic effects and development of resistance due to high systemic exposure 4, 5 . Due to poor pulmonary tissue diffusion of the administered drugs, the drug concentration achieved in the lungs is in the sub-therapeutic range, when given by these conventional routes. Thus, the situation has come to a point where the development of novel intervention strategies is urgently needed.
A well-explored way to deliver anti-TB drugs is via the pulmonary route by which high concentrations can be achieved in the lungs which would be coupled with low systemic bio-distribution and toxicity. The ways of direct pulmonary administration of drugs include nebulization of drug solutions or particulate formulations including nanoparticles, liposomes and microparticles.
In this regard, inhalable therapy has great potential, allowing the direct administration of drugs to the infection site. This approach would potentially enable reducing the dosing frequency and shorten the treatment duration, thereby avoiding severe systemic side effects and improving patient compliance. Implementing this therapeutic strategy requires the design of antitubercular inhalable formulations with ISSN: 2250-1177 [14] CODEN (USA): JDDTAO suitable aerodynamic properties to reach the alveoli, where the alveolar macrophages infected with M. tuberculosis are located.
Substantial research has been done to develop alveolar macrophage targeting for pulmonary delivery wherein the drugs are entrapped in polymers, copolymers and lipids. Such formulations include microparticles [6] [7] [8] , nanoparticles 5, 9 , solid lipid nanoparticles 2 etc.
Chitosan is deacetylated derivative of chitin, is widely distributed in nature and has been widely used as a drug carrier offering advantages of mucoadhesivity, good biocompatibility, non-immunogenicity, and non-toxicity 10, 11 . Over the years, micro and nano-particulate carrier systems composed of chitosan polymer have widely been studied for the delivery of drugs and bio-macromolecules. It displays unique property of binding to the cell membrane which is manifested as enhancement in its cellular uptake and transfection efficiency.
Ascorbic acid is a well-known antioxidant present in cells and plasma of humans. Its beneficial effect and antioxidant properties have been widely studied. But due to unstability, get oxidised to dehydroascorbic acid in light air and temperature. To increase the stability of Ascorbic acid various derivatives have been synthesized, including the metal salts (Na, Ca salts), ethers, esters and the polysaccharide derivatives 12 . Here chitosan properties combined with ascorbic acid by formation of chitosan ascorbate, a soluble ketimine formed due to salification of chitosan has shown increased stability, antioxidant properties, permeability and adhesiveness. Applications of chitosan properties with ascorbic acid applied previously in various field wound healing 13 , vaginal delivery of peptides 14 .
Interestingly, one finding has demonstrated that ascorbic acid sterilized he culture of drug susceptible and drug resistant mycobacterium tuberculosis the generation of highly reactive hydroxyl radicals via the Fenton reaction 15 .
Recently, it has been investigated that ascorbic acid had no activity by itself in M. tuberculosis-infected mice, the combination of it with the first line TB drugs reduced the bacterial burden in the lungs of M. tuberculosis-infected mice faster than drug alone 16 .
To the best of our knowledge, we believe so far there are no reports on the synthesis of chitosan ascorbate microspheres for pulmonary delivery of antitubercular drugs. In view of its unique properties reported earlier with little knowledge about the nano form of this compounds characteristics 17 , the present study aims to investigate the microspherical formation, its physiochemical properties, antioxidant efficacy, in-vitro drug release and lung deposition study, cytotoxicity on A549 cell line. We hypothesize that this proposed approach would surmount precise toxicity limitations and be a utile choice of carrier system based drug delivery with therapeutic properties.
MATERIALS AND METHODS
Isoniazid (purity˃99%) was received as a gift sample by Lupin Ltd, Aurangabad (Maharashtra India). Chitosan have degree of deacetylation (80.0-95%), sodium tripolyphosphate (STPP), L-Ascorbic acid (99%), FITC Dye were purchased from Sigma-Aldrich, India. Methanol and Acetonitrile (HPLC grades) was purchased from CDH chemicals. DMEM Medium with High Glucose and Fetal Bovine Serum (FBS), Penicillin-Streptomycin Solution, FITC and MTT were purchased from Sigma Co., Ltd. All the chemicals and ingredients utilized for studies were of AR grade. Double distilled water was utilized throughout the study.
Preparation of Mannosylated Chitosan Ascorbate Microsphere (m-CAMs):
Mannosylated Chitosan Ascorbate Microspheres (m-CAMs) were prepared by a two-step process involving (i) in-situ synthesis of Chitosan Ascorbate Microsphere (CAMs) and (ii) mannosylation of above prepared CAMs (m-CAMs).
CAMs were synthesized by modified ionotropic gelation. 1.5 % (w/v) low molecular weight chitosan powder was added to 1.0 M ascorbic acid solution and stirred continuously until a clear solution obtained. The solution was allowed to stand for 3 h. Then addition of 5 % (w/v) STPP solution at 8 ml/min flow rate and 800rpm (Multistage magnetic stirrer, Velp, Italy) for 30 min. The dropping rate and falling distance of STPP solution were kept constant. Then spontaneously formed microsphere suspension was kept overnight then centrifuge at 5000 rpm for 5 min. The microspheres were washed two times with distilled water, laid out on aluminium trays, and dried until weight remains constant. INH loaded Chitosan Ascorbate microsphere (INH-CAMs) were prepared using the procedure just described, except INH (100mg) dissolved initially in chitosan solution. Optimization studies performed to achieve optimum size of formulation for pulmonary delivery of INH [ Table 1 ]. Mannosylation was carried out by adopting the method describe 18, 19 with certain modification. The coupling of mannose to the amine group of chitosan was carried out in two steps. In first step, coupling reaction done initially where D-mannose (10 µm) was dissolved in 0.1 M sodium acetate buffer at pH 4 and 60 • C for 2 hr resulting in the ring opening of mannose molecule. In second step, this solution was mixed thoroughly with chitosan microsphere synthesized earlier and incubated for 24 hr at room temperature. The aldehyde group of ring opened mannose reacts with amine group of chitosan, yielding mannosylated chitosan and the resulting solution centrifuged at 5000rpm and washed thoroughly with distilled water.
Purification of m-CAMs: Formulation were purified by dialyzing against double distilled water in a dialysis tube (>900KDa MWCO) for 24 hr to remove any unreacted drug and polymer.
Physico-chemical characterization of carrier system:

Particle size Analysis and morphological characteristics:
Particle size was determined by digital photographic microscope and Malvern ZetaSizer (Mastersizer X, Malvern Instruments Ltd., UK). For determination of particle size, the microspheres were suspended in methanol containing 0.1% Tween 80 to prevent aggregation, and the mean particle size and polydispersity index were determined. For determination of zeta potential, the microspheres were suspended in de-ionized water and placed in disposable polystyrene electrophoretic cells. The total zeta runs were 100 and the count rate was 250 particles/sec. The experiments were performed in triplicate.
The surface characteristics were studied by scanning electron microscope (Model JSM-6390A, JEOL, Japan) from 5X to 300000X magnifications at the MSME Department, MANIT, Bhopal India. The powder sample was sprinkled onto the carbon tape affixed on aluminium stubs. The aluminium stubs were placed in the vacuum chamber and observed for morphological characterization.
Powder X-ray Diffraction (PXRD) Studies: PXRD were determined for drug and drug loaded carrier systems CAMs and m-CAMs. Samples were exposed to a monochromatic nickel-filtered copper radiation (40 kV, 30 mA) in a wideangle X-ray diffractometer (XPERT-PRO system) with 2θ angle.
FTIR Study: Samples were prepared in KBr disc (4 mg sample/200 mg KBr) using a hydrostatic press at a force of 40 psi for 4 min. Each sample was scanned thrice between 4000 and 400 cm −1 at a resolution of 4 cm −1 and averaged for that sample and there were three (n = 3) different samples scanned.
Differential scanning calorimetry (DSC):
DSC was performed for chitosan, ascorbic acid and CAMs using a PyrisTM Diamond DSC (PerkinElmer). Accurately weighted samples (5±0.1 mg) were used for the analysis, and it was sealed in aluminum pans. They were scanned from 50ºC to 350 ºC at 10 ºC/ min.
Antioxidant activity assay:
Antioxidant activity assay performed for chitosan ascorbate microsphere by following method 20, 21 . Different concentrations of testing samples and 2 mL of DPPH ethanol solution (180 μmol/L) were incubated for 30 min at room temperature. Then, the absorbance of the remained DPPH radical was measured at 517 nm against a blank. Three replicates for each sample were tested and the DPPH-radical scavenging effect was calculated according to the following equation:
Where Asample 517 nm is the absorbance of the samples, Acontrol 517 nm is the absorbance of the control (DPPH was substituted with ethanol), and Ablank 517 nm is the absorbance of the blank (samples were substituted with distilled water). Pure ascorbic acid solution was used as a positive control.
In-vitro lung deposition study:
In-vitro lung deposition pattern of formulation determined by an Andersen Cascade Impactor (ACI) (Thermofisher Scientific, U.K.) by calculated parametrs i.e. percent emitted dose (% ED), mass median aerodynamic diameter (MMAD) and fine particle fraction (FPF) of various formulations. Optimized formulations having higher drug loading were selected for this study and accurately weighted amount was mixed with micronized lactose at a 1:3 (w/w) ratio and dosed in an eight-stage nonviable Anderson cascade impactor. After the completion of dosing) % ED, MMAD and FPF were calculated from the deposition data using the MMAD calculator for Anderson apparatus using a flow rate of 28.3 L/min. The experiment was performed in triplicate. The drug distribution to various organs/tissues after intratracheal administration of microspheric formulations by aerosolization was performed using a MicroSprayerTM aerosoliser (IA-1C; Penn-Century, Philadelphia, PA, USA), attached to a high-pressure syringe (FMJ-250; Penn-Century). This device is an aerosol generator consisting of a sub-miniaturized atomizer located in the tip of a 1.25' stainless steel tube, which is attached to a hand operated, high-pressure syringe. Animals were divided into four groups (Table 5) , each containing six animals (n=6). Group 1 animals keep as a controlled and animals of group 2 were administered with 5 mg INH in 500µl sterilized phosphate buffer saline through intra-trachea insillation. Similarly, group II and III received both formulations CAMs and m-CAMs respectively, equivalent to 5 mg drug, dispersed in 500µl PBS. Following the drug administration, blood was collected after 1, 2, 4, 8, 12 and 24 hr through retro orbital plexus. Collected blood sample 0.5 ml were centrifuge at 1000 rpm for 20 min; plasma was separated and filtered through membrane filter 0.45 µm. At the same time, selected organs (lungs, liver, spleen, and kidney) were excised, isolated, dried, weighed, and stored at -80ºC 28 . In the bio-distribution study, the stored isolated organs were recovered from deep freezer and kept out-side for some time at room temperature. Each tissue weighed separately, minced into pieces, and homogenized by tissue homogenizer (WiseMix HG-15D, Dathan Scientific, New Delhi, India) in phosphate buffer. The homogenized tissues were deproteinized with acetonitrile, vortexed (Swirlex-Vortex Shaker, Tarson Make) for 5 min, centrifuged at 5000g for 10 min at 4-8 ºC, kept in dark for 30 min and filtered. Supernatant was filtered through a membrane filter and used for the analysis of INH upon suitable dilution with mobile phase by HPLC technique and compared with calibration graphs (obtained by analyzing pooled blank plasma spiked with known drug amounts) to obtain the plasma drug concentration versus time profile 29 .
In-vitro
Stastical analysis:
Results were reported as mean ± Standard Deviation (SD) for the different parameters assessed. Student's t-tests and One-Way Analysis of Variance (ANOVA) were used to compare between the independent variables, for two groups and more than two sets of data, respectively. For this purpose, IBM Statistical Package for Social Sciences (IBM SPSS® Statistics-version 21) was used, and the difference was considered statistically significant when the calculated p-value was less than 0.05.
RESULT AND DISCUSSION
Preparation of carrier system:
For preparation of chitosan ascorbate microsphere (CAMs) chitosan ascorbate solution were prepared by salification of chitosan in ascorbic acid then resulting solution formed in a stable condition. Solubilization of chitosan by ascorbic acid due to the reactive amino groups in chitosan chains can be protonated by ascorbic acid molecules and form a positively charged water-soluble solution (Fig 1) 30 . The amount of chitosan conjugated with ascorbic acid was determined using ninhydrin method as a reagent to react with primary and secondary amine group in the polymer with various concentrations 31, 32 . The percent degree of substitution was determined by comparing the slope obtained from standard D-glucosamine and chitosan and shown in Fig.2 .
Eventually, chitosan ascorbate microspheres (CAMs) were synthesized by modified ionic gelation method using STPP into an aqueous solution of chitosan ascorbate. Chitosan, a polycationic polysaccharide is insoluble in alkaline and neutral pH, but in acidic condition, protonated amine group of chitosan interacts with phosphate ions provided by STPP ion, either by intermolecular or intramolecular linkage [33] [34] [35] . Particle size of microspheres formed majorly depends on the ascorbic acid concentration and degree of deacetylation. Chitosan with higher degree of deacetylation makes it susceptible to provides more number of effective binding sites for the ionic interaction with ample positive charge due to amino groups that protonated in the acidic environment 36 . Whereas the increment in the concentration of ascorbic acid in which chitosan was dissolved also enhancing the ability of chitosan to form linkage with STPP anion hence microspheres decrease in particle size (Table 1) . During optimizing the formulation, as we increased concentration of chitosan, the zeta potential increased due to the increase in the positive charge of the chitosan molecules. Higher chitosan concentration caused more unneutralized -NH3 + on the microspheres surface, which led to a strong electrostatic repulsion between particles 37 . This confirms that the formation of microspheres greatly depends on the concentration of free amine groups which increase the surface charge and zeta potential of the microspheres. In addition, when increasing the concentration of chitosan, the particle size increased in a linear manner with a correlation coefficient. The same result was obtained by several authors 38 .
Increasing the concentration of STPP, reduced the zeta potential of micropsheres because at higher concentration, STPP brings more negatively charged phosphate ions which react with chitosan amino groups. Therefore, the positive surface charge of the microspheres decreases. In addition, the microspheres size increased when increasing STPP concentration. At low STPP concentrations (1%), the amount of TPP was not enough to fully crosslink chitosan chains, and the preparations remained transparent. Further increase in TPP concentration (5%) led to an increase in particle size and to a slightly opaque solution. At higher TPP concentration (10 %), very large and polydispersed particles were obtained. The same result was reported already 39 who observed physical states of chitosan-TPP microspheres being either suspension (below a certain TPP concentration which depends on chitosan concentration) or precipitation (above a certain TPP concentration) in the range of TPP concentrations tested. However, optimized particle size was found to be increased to 4.10±1.58 µm upon mannosylation. The increase in particle size after conjugation with mannose and zeta potential turned invert (Table. 2) can be due to the surface anchoring of mannose moieties to the amine groups present on the surface of CAMs 19 . 
Characterization
Ascorbic acid solubilizes the chitosan because chitosan contains amino groups which are protonatable in the acidic media, whereas ascorbic acid contains acidic hydroxyl functionality, thus allowing the formation of a complex through ionic interaction. Interaction between chitosan polymer and ascorbic acid during solublization was investigated by FTIR study (Fig. 2 and Table 3 ). FTIR spectra of chitosan shows in Fig. 3(a) , a characteristic strong peak at 3417.5 cm −1 was attributed to overlapping stretch vibrations of -NH2 and -OH groups and the peak for amide I (C=O) at 1643.7 cm −1 was seen. The aliphatic C-H stretching vibration of the polymer backbone occurred at 2923.6 cm −1 40 . The weak deformation vibration of C-CH3 appeared at 1383.8 cm −1 , indicating a higher degree of deacetylation of CS used in this experiment (Zhang et al. 2014 ). In FTIR ascorbic acid showed in Fig. 3(b Fig. 3 (c) -NH2 groups on the Chitosan chains were protonated by the H + supplied by Ascorbic acid. The decrease of peak at 3428.2 cm −1 in indicated the reduction of free -NH2 groups after solubilize the chitosan with ascorbic acid. 
b). Ascorbic acid and c). After solubilisation
To characterize the mannosylation on CAMs system, in the mannose ligand, aside of the broad O-H band in the 3391cm -1 range, the minimum transmittance was in the 950-1200cm −1 region where the C-O-C and C-O-H link band positions are found. The two shoulder peaks at 1064 and 1324 cm −1 can be attributed to the glycosidic links of mannose 42 . The characteristic wave numbers that can be used for the quantification of mannose, viz., 1157.5, 1294.8
and 916.2 were present in mannosylated chitosan ascorbate microspheres. FTIR studies on mannosylated chitosandisplayed decreasing intensities with peak broadening for various bands of chitosan as well as of mannose, implying an interaction between these chemical moieties. This clearly confirmed the presence of mannose on m-CAMs carrier system (Fig. 4) . 
Entrapment efficiency:
The results confirmed the better entrapment efficiency of INH in both CAMs and m-CAMs. The possible reason may be the hydrophilicity of INH and being hydrophilic in nature polymeric matrix provided a safe home to hydrophilic INH. Further the lower drug entrapment in case of mannosylated carrier system as compare to plain, may possibly be due to the during mannosylation reaction that involves incubation in sodium acetate buffer (pH 4.0) for period of 24 h which might have led to leaching of drug in reaction medium.
SEM Analysis:
From the SEM photographic image it was observed that the optimized microspheres (CAMs and m-CAMs) were spherical in shape, they did not form agglomerations, and their surfaces were slightly smooth. The particle size obtained from SEM photography is close to the particle size obtained using the digital photographic microscope (Fig. 5 ). Diffraction spectrum of INH showed distinct and high intensity peaks in the region of 2θ ranging from 15• to 25• . INH displays PXRD pattern with sharp and intense peaks, denoting a highly crystalline structure. The pattern matches that described in the literature 43 and no other peaks than those belonging to the INH crystalline phase were found. However, in case of INH-loaded CAMs, no such peaks could be observed. This could have occurred due to entrapment of drug within the microspheres. From these observations, we concluded that the drug was efficiently loaded within the microspheres and the amount of surface-adsorbed drug could be considered as negligible. The diffractograms of the INH loaded CAMs and m-CAMs for INH are shown the typical XRD peaks of both systems. When the drug was loaded into chitosan polymer in the form of microspheres the intensity of each peak markedly decreased. This is a sign of the drug(s) inclusion into both CAMs and m-CAMs formulations.
In-vitro lung deposition study
Removal of drug with delivery system and aerosolisation performance for carrier system was investigated using Andersen Cascade Impactor (ACI). The ACI is comprised of different plates or stages corresponding to the different regions of the respiratory system, from the oral cavity to alveoli. The particulate matter is drawn at a predetermined air-flow rate through the apparatus, resulting in deposition of the particles on different plates of ACI as a function of their particle size and aerodynamics.
The ACI is similar to a twin stage impinger (TSI) in function. However in addition to particle size, it gives a detailed lung deposition data with additional parameters like %ED, MMAD and FPF. Mass Median Aerodynamic Diameter (MMAD) represents the average diameter below which 50% of the particles remain. The emitted dose (ED), i.e. the mass of drug deposited in the induction port, the stages and the filter, was expressed as the percentage (%ED) of the total recovered mass (i.e. from the induction port, the stages and the filter from the adapter, the inhaler and capsule) whereas FPF is generally regarded as the fraction of the total inhaled dose that reaches the stages corresponding to the cut-off diameter of 5 µm.
The % ED values for all microspheres were high in the range from 85.1% to 89.6%, and this corresponds to minimal retention in the capsule and indicating that the microsphere powder was efficiently emitted from the Inhaler 46 . MMAD value for microspheres were found (between 2-5 μm) satisfactory for delivery to the alveoli where the mycobacterium infection is mainly present (Fig. 7 ). The lower MMAD and high FPF found with formulation of mannosylated carrier system that shown prepared formulation compatible with dry powder for inhalation. The %FPF depicted that the larger dose was available to the lungs after inhalation hence it help to target the formulation towards alveolar macrophage cells where the tubercular bacilli reside.
In-vitro drug release:
The release studies were carried out in two different simulated lung fluids as release medium, which is used to evaluate human exposure to particulates from environmental emissions. ALF is analogous to the fluid with which inhaled particles would come into contact after phagocytosis by alveolar and interstitial macrophages in the lung. Gamble's solution represents the interstitial fluid deep within the lung.
Cumulative In-vitro release profile of INH loaded CAMs and m-CAMs were presented in Fig. 8 (a and It can be concluded that the developed formulations were able to release the drug in sustained manner in the phagolysosomal bio milieu. The release pattern of drug from both microsphere formulations followed a biphasic pattern, characterized by an initial burst, followed by a slower sustained release. The initial burst release may be due to the release of the drug present at or just beneath the surface of microspheres. Thereafter the release occurred due to the polymer erosion and diffusion of the drug molecules. The diffusion of drug(s) is through small pores and channels in the polymer matrix. Hence our carrier system releases drug inside Alveolar macrophage at late phagosomal phase of phagocytosis in controlled manner by erosion mechanism which may help in reduction in dosing frequency of drug, so this delivery system will be able to retain high amount of drug in the acidic pH and would be able to release more drug in the alveolar macrophages at the desired site of drug 47, 48 .
In vitro cell proliferation study:
The cytotoxic effects of INH against A549 cells were examined by MTT assay. In the experiments, the cytotoxicity was evaluated by varying the concentration of free INH solution, drug loaded CAMs and m-CAMs. Cytotoxicity was observed to be INH concentration-dependent for all the tested samples (Fig. 9 ). The highest cytotoxic effects were found for free INH, which even in the lowest concentration (20 µl/mL) showed only a 55% cell viability that further decreased to 20% when the free drug was used in the highest concentration (100 µl/mL). These results show the high toxicity of INH that can cause side effects also when it is nebulized directly into the lung, where is the site of infection. The viability assay also showed that INH toxicity can be reduced by entrapped the drug in chitosan microspheres. Cell viability was generally not affected by chitosan concentration, in fact empty particles showed always the best results in term of viability. As can be seen in Fig. 9 , the presence of mannosylation slightly decreased the viability of cells probably may be because of STPP was in the microspheres also after the purification steps. Various pharmacokinetic parameters such as Cmax (µg/ml), Tmax (h), and AUC 0-24 (µg h/ml) of the developed optimized microspheric formulation was determined and compared with the plain INH solution (Table: 6 ) and organ distribution of drug in various organs shown in Fig.10 (A-D). It was observed that peak plasma concentrations of the drug were achieved quickly in case of plain drug compared with the developed formulation. A significant higher Tmax and AUC in experimental formulation could be related to controlled and localized drug delivery under the physiological conditions. The higher values of AUC of developed formulations clearly indicated that drug concentrations were maintained within the pharmacologically effective range for longer period of time.
From in vivo studies, it was observed that there was a significant increase in drug accumulation within the desired cellular tropics when they were administered in microspheric form (CAMs and m-CAMs) formulations. As expected, the plasma and organ distribution studies had shown higher amount of drug(s) recovery from lungs in the case of both the ligand conjugated formulations as compared to plain counterparts and free drug, indicating the efficacy of developed carrier for lung targeting of INH. 
CONCLUSION
Inhalable chitosan ascorbate microsphere were successfully prepared by salification of chitosan with ascorbic acid and then fabricated by ionic gelation method, hence the captivative antioxidative potential and non-toxic nature of carrier system in which first line antitubercular drug (INH) incorporated for treatment of pulmonary tuberculosis. The microsphere then further mannosylated to m-CAMs, so targetability of isoniazid to alveolar macrophages increased. The microsphere did not affect the viability of A549 cells during in-vitro condition. Overall, results obtained from various studies so far indicate a potential application of the proposed systems in pulmonary tuberculosis therapy. Hence this approach for delivery of isoniazid loaded mannospylated chitosan microspheres to alveolar macrophages has been successfully attempted.
